GlycoMimetics reports Q3 2022 financials; FDA clears interim analysis for uproleselan Phase 3

CRESCENT BIOPHARMA, INC.

Cash $51.6M as of Sep 30, 2022 vs $90.3M at Dec 31, 2021; cash runway extended to end of 2023.
FDA cleared protocol amendment for interim utility analysis of uproleselan Phase 3 in relapsed/refractory AML.
Blinded pooled survival data show patients living longer than historically expected; DMC meeting by end Q1 2023.
Final survival events trigger projected around year-end 2023, later than originally anticipated.
R&D expenses decreased to $4.9M from $13.3M YoY due to Phase 3 enrollment completion.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

CRESCENT BIOPHARMA, INC. reported third quarter ended September 30, 2022 results: revenue There was no revenue recognized during the three months ended September 30, 2022.

Period: third quarter ended September 30, 2022
Revenue: There was no revenue recognized during the three months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 9, 2022, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-22-017028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.